Exploring innate glycopeptide resistance mechanisms in Staphylococcus aureus.
作者信息
Renzoni Adriana, Kelley William L, Vaudaux Pierre, Cheung Ambrose L, Lew Daniel P
机构信息
Service of Infectious Diseases, Geneva University Hospital, CH-1211 Geneva 14, Switzerland.
出版信息
Trends Microbiol. 2010 Feb;18(2):55-6. doi: 10.1016/j.tim.2009.11.005. Epub 2009 Dec 11.
Abstract
摘要
相似文献
1
Exploring innate glycopeptide resistance mechanisms in Staphylococcus aureus.
Trends Microbiol. 2010 Feb;18(2):55-6. doi: 10.1016/j.tim.2009.11.005. Epub 2009 Dec 11.
2
Glycopeptide resistance in Staphylococcus aureus.
J Antimicrob Chemother. 2003 May;51(5):1309-11. doi: 10.1093/jac/dkg196. Epub 2003 Mar 28.
3
Antibiotic resistance in Staphylococcus aureus and its relevance in therapy.
Expert Opin Pharmacother. 2005 Oct;6(13):2257-69. doi: 10.1517/14656566.6.13.2257.
4
The problem with glycopeptides.
Int J Antimicrob Agents. 2007 Jul;30(1):1-3. doi: 10.1016/j.ijantimicag.2007.03.006. Epub 2007 May 15.
5
Glycopeptides--important treatment option for methicillin-resistant Staphylococcus aureus.
Indian J Med Microbiol. 2011 Jul-Sep;29(3):313-4. doi: 10.4103/0255-0857.83922.
6
Bactericidal activity of oxacillin and glycopeptides against Staphylococcus aureus in patients with endocarditis: looking for a relationship between tolerance and outcome.
Ann Clin Microbiol Antimicrob. 2011 Jun 9;10:26. doi: 10.1186/1476-0711-10-26.
7
Loss of function of the gdpP protein leads to joint β-lactam/glycopeptide tolerance in Staphylococcus aureus.
Antimicrob Agents Chemother. 2012 Jan;56(1):579-81. doi: 10.1128/AAC.05148-11. Epub 2011 Oct 10.
8
Synthesis and antibacterial activity of N4-mono alkyl derivatives of novel glycopeptide LYV07ww01.
Bioorg Med Chem Lett. 2011 Nov 15;21(22):6732-8. doi: 10.1016/j.bmcl.2011.09.045. Epub 2011 Sep 18.
9
Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
Clin Microbiol Infect. 2006 Jan;12(1):92-5. doi: 10.1111/j.1469-0691.2005.01306.x.
10
Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK.
J Antimicrob Chemother. 2010 Apr;65(4):721-4. doi: 10.1093/jac/dkq009. Epub 2010 Feb 2.
引用本文的文献
1
Methicillin-Resistant (MRSA): Resistance, Prevalence, and Coping Strategies.
Antibiotics (Basel). 2025 Jul 30;14(8):771. doi: 10.3390/antibiotics14080771.
2
Staphylococcus aureus with reduced susceptibility to vancomycin in healthcare settings.
J Prev Med Hyg. 2014 Dec;55(4):137-44.
3
Prevalence of isolates with reduced glycopeptide susceptibility in orthopedic device-related infections due to methicillin-resistant Staphylococcus aureus.
Eur J Clin Microbiol Infect Dis. 2012 Dec;31(12):3367-74. doi: 10.1007/s10096-012-1705-8. Epub 2012 Jul 26.
4
The posttranslocational chaperone lipoprotein PrsA is involved in both glycopeptide and oxacillin resistance in Staphylococcus aureus.
Antimicrob Agents Chemother. 2012 Jul;56(7):3629-40. doi: 10.1128/AAC.06264-11. Epub 2012 Apr 23.
5
High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2012 Mar;56(3):1258-64. doi: 10.1128/AAC.05808-11. Epub 2011 Dec 12.
6
Site-specific mutation of Staphylococcus aureus VraS reveals a crucial role for the VraR-VraS sensor in the emergence of glycopeptide resistance.
Antimicrob Agents Chemother. 2011 Mar;55(3):1008-20. doi: 10.1128/AAC.00720-10. Epub 2010 Dec 20.
7
Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.
Antimicrob Agents Chemother. 2010 Sep;54(9):3861-70. doi: 10.1128/AAC.00269-10. Epub 2010 Jun 14.
本文引用的文献
1
Identification by genomic and genetic analysis of two new genes playing a key role in intermediate glycopeptide resistance in Staphylococcus aureus.
Antimicrob Agents Chemother. 2009 Mar;53(3):903-11. doi: 10.1128/AAC.01287-08. Epub 2008 Dec 22.
2
Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus.
Antimicrob Agents Chemother. 2008 Oct;52(10):3755-62. doi: 10.1128/AAC.01613-07. Epub 2008 Jul 21.
3
Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci.
PLoS Pathog. 2007 Jul 27;3(7):e102. doi: 10.1371/journal.ppat.0030102.
4
Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.
Proc Natl Acad Sci U S A. 2007 May 29;104(22):9451-6. doi: 10.1073/pnas.0609839104. Epub 2007 May 21.
5
Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
Antimicrob Agents Chemother. 2007 Aug;51(8):2679-89. doi: 10.1128/AAC.00209-07. Epub 2007 May 14.
6
The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.
Clin Infect Dis. 2007 May 1;44(9):1208-15. doi: 10.1086/513203. Epub 2007 Mar 28.
7
Strain dependence of the cell wall-damage induced stimulon in Staphylococcus aureus.
Biochim Biophys Acta. 2006 Oct;1760(10):1475-81. doi: 10.1016/j.bbagen.2006.06.008. Epub 2006 Jul 1.
8
Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.
Antimicrob Agents Chemother. 2006 Mar;50(3):1079-82. doi: 10.1128/AAC.50.3.1079-1082.2006.
9
Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin.
J Bacteriol. 2006 Feb;188(3):1120-33. doi: 10.1128/JB.188.3.1120-1133.2006.
10
DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus.
Antimicrob Agents Chemother. 2005 Aug;49(8):3404-13. doi: 10.1128/AAC.49.8.3404-3413.2005.
Zotero 插件